Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$129.45
-3.82-2.87%
À la fermeture: -
$129.00
-0.45-0.35%
Après les heures de négociation: 5:37 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Abbott Laboratories a un objectif de cours consensus de $142.26, basé sur les évaluations des 24 analystes. Le plus élevé est de $159 attribué par Barclays le avril 17, 2025, et le plus bas est de $120 attribué par Jefferies le septembre 26, 2024. Les 3 dernières évaluations d'analystes ont été publiées par Benchmark, Evercore ISI Group et Citigroup le octobre 10, 2025, octobre 7, 2025 et juillet 18, 2025. Avec un objectif de cours moyen de $148 entre Benchmark, Evercore ISI Group et Citigroup, il y a une variation implicite de 14.73% upside pour Abbott Laboratories à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
Benchmark
Evercore ISI Group
Citigroup
Wells Fargo
Raymond James
1calculé à partir des notes des analystes
Notes d'analystes pour Abbott Laboratories
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/10/2025 | 12.4% | Benchmark | → $145 | Initiates | → Buy | |||
10/07/2025 | 11.63% | Evercore ISI Group | $140 → $144 | Maintains | Outperform | |||
07/18/2025 | 20.16% | Citigroup | $157 → $155 | Maintains | Buy | |||
07/18/2025 | 10.08% | Wells Fargo | $147 → $142 | Maintains | Overweight | |||
07/18/2025 | 9.3% | Raymond James | $142 → $141 | Maintains | Outperform | |||
07/18/2025 | 4.65% | Mizuho | $140 → $135 | Maintains | Neutral | |||
07/18/2025 | 12.4% | Jefferies | $143 → $145 | Upgrade | Hold → Buy | |||
07/18/2025 | 12.4% | BTIG | $148 → $145 | Maintains | Buy | |||
07/17/2025 | 8.53% | Evercore ISI Group | $145 → $140 | Maintains | Outperform | |||
07/16/2025 | 8.53% | Mizuho | $130 → $140 | Maintains | Neutral | |||
07/15/2025 | 13.95% | RBC Capital | $145 → $147 | Maintains | Outperform | |||
07/15/2025 | 6.2% | Morgan Stanley | $127 → $137 | Maintains | Equal-Weight | |||
07/14/2025 | 14.73% | BTIG | $145 → $148 | Maintains | Buy | |||
07/09/2025 | 21.71% | Citigroup | $155 → $157 | Maintains | Buy | |||
07/08/2025 | 12.4% | Evercore ISI Group | $140 → $145 | Maintains | Outperform | |||
06/20/2025 | 10.85% | Jefferies | $137 → $143 | Maintains | Hold | |||
04/17/2025 | 12.4% | BTIG | $140 → $145 | Maintains | Buy | |||
04/17/2025 | 11.63% | Bernstein | $138 → $144 | Maintains | Outperform | |||
04/17/2025 | 10.08% | Raymond James | $132 → $142 | Maintains | Outperform | |||
04/17/2025 | 12.4% | Piper Sandler | $133 → $145 | Reiterates | Overweight → Overweight | |||
04/17/2025 | 12.4% | RBC Capital | $140 → $145 | Maintains | Outperform | |||
04/17/2025 | 13.95% | Wells Fargo | $136 → $147 | Maintains | Overweight | |||
04/17/2025 | -1.55% | Morgan Stanley | $117 → $127 | Maintains | Equal-Weight | |||
04/17/2025 | 23.26% | Barclays | $158 → $159 | Maintains | Overweight | |||
04/17/2025 | 12.4% | Stifel | $135 → $145 | Maintains | Buy | |||
04/17/2025 | 6.2% | Jefferies | $135 → $137 | Maintains | Hold | |||
04/16/2025 | 8.53% | Evercore ISI Group | $138 → $140 | Maintains | Outperform | |||
04/15/2025 | 8.53% | RBC Capital | $135 → $140 | Maintains | Outperform | |||
03/10/2025 | 16.28% | B of A Securities | $133 → $150 | Maintains | Buy | |||
03/04/2025 | 24.03% | Citigroup | $135 → $160 | Maintains | Buy | |||
03/04/2025 | 19.38% | Goldman Sachs | $138 → $154 | Maintains | Buy | |||
01/27/2025 | 22.48% | Barclays | $149 → $158 | Maintains | Overweight | |||
01/23/2025 | 4.65% | Jefferies | $125 → $135 | Maintains | Hold | |||
01/23/2025 | 6.98% | Bernstein | $135 → $138 | Maintains | Outperform | |||
01/23/2025 | 4.65% | RBC Capital | $135 → $135 | Reiterates | Outperform → Outperform | |||
01/23/2025 | 5.43% | Wells Fargo | $133 → $136 | Maintains | Overweight | |||
01/23/2025 | 4.65% | Stifel | $130 → $135 | Maintains | Buy | |||
01/23/2025 | 14.73% | UBS | $146 → $148 | Maintains | Buy | |||
01/22/2025 | 8.53% | BTIG | $139 → $140 | Maintains | Buy | |||
01/21/2025 | 4.65% | RBC Capital | $135 → $135 | Reiterates | Outperform → Outperform | |||
01/08/2025 | 4.65% | Bernstein | $138 → $135 | Maintains | Outperform | |||
01/02/2025 | 5.43% | Evercore ISI Group | $128 → $136 | Maintains | Outperform | |||
12/20/2024 | 4.65% | RBC Capital | $130 → $135 | Maintains | Outperform | |||
11/05/2024 | 15.5% | Barclays | $143 → $149 | Maintains | Overweight | |||
10/17/2024 | 6.98% | Bernstein | $133 → $138 | Maintains | Outperform | |||
10/17/2024 | 13.18% | UBS | $143 → $146 | Maintains | Buy | |||
10/17/2024 | -3.1% | Jefferies | $120 → $125 | Maintains | Hold | |||
10/17/2024 | 0.78% | Mizuho | $115 → $130 | Maintains | Neutral | |||
10/17/2024 | 3.1% | Piper Sandler | $131 → $133 | Maintains | Overweight | |||
10/17/2024 | -9.3% | Morgan Stanley | $107 → $117 | Maintains | Equal-Weight | |||
10/16/2024 | 0.78% | Stifel | $125 → $130 | Maintains | Buy | |||
10/16/2024 | -0.78% | Evercore ISI Group | $124 → $128 | Maintains | Outperform | |||
10/16/2024 | 7.75% | BTIG | $135 → $139 | Maintains | Buy | |||
10/14/2024 | — | Raymond James | $122 → $129 | Maintains | Outperform | |||
10/08/2024 | 0.78% | RBC Capital | $125 → $130 | Maintains | Outperform | |||
10/08/2024 | 0.78% | Oppenheimer | → $130 | Initiates | → Outperform | |||
10/01/2024 | -3.88% | Evercore ISI Group | $120 → $124 | Maintains | Outperform | |||
09/26/2024 | -6.98% | Jefferies | $120 → $120 | Reiterates | Hold → Hold | |||
09/19/2024 | 1.55% | Piper Sandler | → $131 | Initiates | → Overweight | |||
08/27/2024 | -6.98% | Jefferies | $112 → $120 | Maintains | Buy | |||
08/22/2024 | -1.55% | Citigroup | $119 → $127 | Maintains | Buy | |||
07/29/2024 | 10.85% | Barclays | $140 → $143 | Maintains | Overweight | |||
07/02/2024 | -6.98% | Evercore ISI Group | $125 → $120 | Maintains | Outperform | |||
06/04/2024 | -3.1% | RBC Capital | $125 → $125 | Reiterates | Outperform → Outperform | |||
05/30/2024 | -6.2% | Goldman Sachs | → $121 | Initiates | → Buy | |||
05/22/2024 | -7.75% | Citigroup | $128 → $119 | Maintains | Buy | |||
04/22/2024 | 8.53% | Barclays | $141 → $140 | Maintains | Overweight | |||
04/18/2024 | -3.1% | RBC Capital | $128 → $125 | Maintains | Outperform | |||
04/04/2024 | -3.1% | Evercore ISI Group | $120 → $125 | Maintains | Outperform | |||
04/03/2024 | -0.78% | Citigroup | $126 → $128 | Maintains | Buy | |||
02/14/2024 | -0.78% | RBC Capital | $128 → $128 | Reiterates | Outperform → Outperform | |||
01/26/2024 | 9.3% | Barclays | $133 → $141 | Maintains | Overweight | |||
01/25/2024 | 3.1% | Wells Fargo | $131 → $133 | Maintains | Overweight | |||
01/25/2024 | -0.78% | RBC Capital | $128 → $128 | Reiterates | Outperform → Outperform | |||
01/25/2024 | -2.33% | Citigroup | $123 → $126 | Maintains | Buy | |||
01/25/2024 | -1.55% | Raymond James | $124 → $127 | Maintains | Outperform | |||
01/16/2024 | 1.55% | Wells Fargo | $121 → $131 | Maintains | Overweight | |||
01/11/2024 | -0.78% | RBC Capital | $119 → $128 | Maintains | Outperform | |||
01/03/2024 | -3.88% | Raymond James | $110 → $124 | Maintains | Outperform | |||
12/13/2023 | -6.2% | Wells Fargo | $116 → $121 | Maintains | Overweight | |||
12/11/2023 | -4.65% | Citigroup | $122 → $123 | Maintains | Buy | |||
10/19/2023 | 3.1% | Barclays | $132 → $133 | Maintains | Overweight | |||
10/19/2023 | -17.05% | Morgan Stanley | $112 → $107 | Maintains | Equal-Weight | |||
10/19/2023 | -10.08% | Wells Fargo | $136 → $116 | Maintains | Overweight | |||
10/19/2023 | -14.73% | Raymond James | $123 → $110 | Maintains | Outperform | |||
10/02/2023 | -13.18% | Jefferies | $120 → $112 | Maintains | Hold | |||
10/02/2023 | -5.43% | Citigroup | $130 → $122 | Maintains | Buy | |||
07/24/2023 | 2.33% | Barclays | $127 → $132 | Maintains | Overweight | |||
07/21/2023 | -13.18% | Morgan Stanley | $112 → $112 | Reiterates | Equal-Weight → Equal-Weight | |||
07/21/2023 | -10.85% | Mizuho | $110 → $115 | Assumes | Neutral → Neutral | |||
07/21/2023 | — | Wolfe Research | — | Upgrade | Underperform → Peer Perform | |||
05/30/2023 | -13.18% | Morgan Stanley | → $112 | Assumes | → Equal-Weight | |||
04/20/2023 | 0.78% | UBS | $117 → $130 | Maintains | Buy | |||
04/20/2023 | -4.65% | Raymond James | $116 → $123 | Maintains | Outperform | |||
04/20/2023 | -1.55% | Barclays | $125 → $127 | Maintains | Overweight | |||
04/20/2023 | 0.78% | Citigroup | $125 → $130 | Maintains | Buy | |||
04/17/2023 | 0.78% | BTIG | $125 → $130 | Maintains | Buy | |||
04/17/2023 | -10.08% | Raymond James | $123 → $116 | Maintains | Outperform | |||
04/10/2023 | 5.43% | Wells Fargo | $140 → $136 | Maintains | Overweight | |||
04/05/2023 | 5.43% | Wells Fargo | $140 → $136 | Maintains | Overweight |
FAQ
Quel est le cours indicatif de l'action Abbott Laboratories (ABT) ?
Le dernier objectif de prix pour Abbott Laboratories (NYSE:ABT) a été rapporté par Benchmark le octobre 10, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $145.00 s'attendant à ce que ABT se rise dans les 12 prochains mois (un possible changement de 12.40% upside). 53 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Abbott Laboratories (ABT) ?
La dernière note d'analyste pour Abbott Laboratories (NYSE:ABT) a été fournie par Benchmark, et Abbott Laboratories initié leur note buy.
Quand a eu lieu la dernière mise à niveau pour Abbott Laboratories (ABT) ?
La dernière amélioration pour Abbott Laboratories a eu lieu le juillet 18, 2025 lorsque Jefferies a augmenté leur objectif de prix à $145. Jefferies avait précédemment a hold pour Abbott Laboratories.
Quand a eu lieu la dernière dégradation pour Abbott Laboratories (ABT) ?
Il n'y a pas de dernière réduction pour Abbott Laboratories.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Abbott Laboratories (ABT) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Abbott Laboratories, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Abbott Laboratories a été déposée le octobre 10, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 10, 2026.
La note d'analyste pour Abbott Laboratories (ABT) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Abbott Laboratories (ABT) était un initié avec un objectif de prix de $0.00 à $145.00. Le prix actuel de Abbott Laboratories (ABT) est de $129.00, ce qui est within la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.